# EDGAR Filing Document

**Accession Number:** 0001533040
**File Stem:** 0001683168-25-006371
**Filing Date:** 2025-8
**Character Count:** 2415
**Document Hash:** d0611a44905d47fee5acb0ad25a046e2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-25-006371.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0001683168-25-006371

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250821

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Phio Pharmaceuticals Corp.
- **CENTRAL INDEX KEY:** 0001533040
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 453215903
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 411 SWEDELAND ROAD
- **STREET 2:** SUITE 23-1080
- **CITY:** KING OF PRUSSIA
- **STATE:** PA
- **ZIP:** 19406
- **BUSINESS PHONE:** (508) 767-3861

**MAIL ADDRESS:**
- **STREET 1:** 411 SWEDELAND ROAD
- **STREET 2:** SUITE 23-1080
- **CITY:** KING OF PRUSSIA
- **STATE:** PA
- **ZIP:** 19406

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RXi Pharmaceuticals Corp
- **DATE OF NAME CHANGE:** 20111019

**PHIO PHARMACEUTICALS CORP.**

**411 Swedeland Road, Suite 23-1080**

**King of Prussia, PA 19406**

August 21, 2025

***VIA EDGAR***

Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attn: Jessica Dickerson

---

| | |
|:---|:---|
| **Re:** | **Phio Pharmaceuticals Corp.** |
|  | **Registration Statement on Form S-3** |
|  | **Filed August 15, 2025** |
|  | **File No. 333-289621** |
|  | **Request for Acceleration of Effective Date** |

---

Dear Ms. Dickerson:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on August 22, 2025, or as soon thereafter as possible.

Please direct any questions or comments concerning this request to Amanda Brown of Hogan Lovells US LLP at (267) 675-4683. Also, please notify Ms. Brown when this request for acceleration has been granted.

Very truly yours,

**PHIO PHARMACEUTICALS CORP.**

By: <u>/s/ Robert J. Bitterman</u> 

Name: Robert J. Bitterman

Title: President and Chief Executive Officer

cc: Amanda Brown, *Hogan Lovells US LLP*